Women’s Health Therapeutics Market size to exceed USD 69.5 Billion by 2034

Selbyville, DE. - The global women's health therapeutics market was valued at USD 44.6 billion in 2024 and is expected to grow from USD 46 billion in 2025 to USD 69.5 billion in 2034, at a CAGR of 4.7%, according to the latest report published by Global Market Insights Inc.

Conditions like endometriosis, menopause-related issues, polycystic ovary syndrome (PCOS), and osteoporosis is increasingly common. This growing disease burden is pushing demand for more effective and targeted therapeutics.

Key Insights:

Market Size & Growth:

• 2024 Market Size: USD 44.6 billion
  
• 2025 Market Size: USD 46 billion
  
• 2034 Forecast Market Size: USD 69.5 billion
  
• CAGR (2025–2034): 4.7%
  

• Regional Insights:

• Largest Market: North America
  
• Fastest Growing Market: Asia Pacific
  
• Emerging Countries: China, India, Brazil, Mexico, South Africa
  

• Key Growth Drivers:

1. Increased awareness and advocacy: Awareness campaigns by NGOs, governments, and social influencers have reduced stigma around women’s health topics like menstrual health, sexual wellness, and menopause, leading to increased diagnosis and treatment rates.
   
2. Technological advancements in drug development: Biotechnology, personalized medicine, and novel drug delivery systems are expanding therapeutic options, improving efficacy, and reducing side effects in women’s health treatments.
   
3. Growing investments and funding: Pharma and biotech companies, as well as VC firms, are increasingly investing in women’s health startups and research.
   
4. Supportive government policies and reimbursement: Governments and health authorities in several countries are supporting women’s health through policy initiatives, insurance coverage, and reimbursement programs, especially for maternal care, contraception, and cancer screening/treatment.
   
5. Aging female population: As global life expectancy increases, so does the population of postmenopausal women, which raises demand for therapies addressing age-related conditions like osteoporosis, cardiovascular disease, and hormone replacement therapy.
   

• Key Players:

• Pfizer led the market with over ~15% share in 2024.
  
• Some of the top players in this market, including Amgen, Pfizer, Merck, Bayer, and AbbVie, which together held a ~45-50% share in 2024.
  

• Key Challenges

1. Underfunding and limited R&D focus: Historically, women's health has received less investment and research attention compared to other therapeutic areas, slowing innovation and new drug development.
   
2. Regulatory hurdles: Developing and approving women-specific drugs, especially hormonal therapies, face stringent regulatory scrutiny, which can delay market entry and increase costs.
   
3. Social stigma and cultural barriers: In many regions, topics like reproductive health, menstruation, and menopause are still taboo, limiting awareness, diagnosis, and treatment uptake.
   
4. Gender bias in clinical trials: Women have been underrepresented in clinical research, leading to gaps in safety and efficacy data for treatments targeted specifically at female biology.
   
5. Access and affordability issues: High treatment costs and uneven healthcare access, especially in low- and middle-income countries, limit the reach of effective therapeutics to women who need them most.
   

Browse key industry insights spread across 140 pages with 180 market data tables and figures from the report, “Womens Health Therapeutics Market Size - By Drug Type, By Application, By Age Group, By Medication Type, By Distribution Channel, Growth Forecast, 2025 - 2034” in detail, along with the table of contents:

https://www.gminsights.com/industry-analysis/womens-health-therapeutics-market

Increasing Adoption of Hormonal Therapies

The hormonal therapies segment held a significant share in 2024, driven by the rising demand for treatments that address conditions such as menopause symptoms, endometriosis, and hormonal imbalances. As awareness grows around hormone replacement therapy (HRT) and the long-term health impacts of untreated hormonal issues, more women are seeking medical intervention. The market has seen continuous innovation in delivery mechanisms, including patches, gels, and sustained-release implants, which enhance patient compliance.

Rising Prevalence of Contraception

The contraception segment generated a sizeable share in 2024, driven by rising demand for both long-acting reversible contraceptives (LARCs) and non-hormonal options. Modern lifestyles, delayed family planning, and growing public health support for reproductive autonomy have fueled adoption across a broad demographic. The market is evolving beyond traditional oral contraceptives, with innovations in vaginal rings, intrauterine devices (IUDs), and injectable formats.

Prescription to Gain Traction

The prescription segment held a substantial share in 2024, owing to the clinical nature of most treatments for conditions like osteoporosis, fertility issues, and gynecological cancers. Physicians remain key decision-makers, and patient trust in prescribed medications continues to drive brand loyalty. Regulatory approval pathways, formulary positioning, and insurance coverage significantly impact sales performance in this segment.

North America to Emerge as a Propelling Region

North America womens health therapeutics market is poised to grow at a decent CAGR during 2025-2034. The region benefits from advanced healthcare infrastructure, strong regulatory oversight, and high awareness levels among both patients and providers. Market players are capitalizing on favorable reimbursement policies and rising demand for targeted treatments across various stages of a woman's life cycle, from adolescence to post-menopause.

Major players in the women’s health therapeutics market are Theramex, Cipla, Kissei Pharmaceutical, Evofem, Pfizer, Shionogi, Ferring, Organon, Amgen, Besins, Allergan (AbbVie), Sanofi, Gedeon Richter, Lupin, Atossa Therapeutics, Novartis, Johnson & Johnson, and Bayer.

To strengthen their market foothold in the women’s health therapeutics space, companies are focusing on a multi-pronged approach. Key strategies include expanding product pipelines through in-house R&D and licensing deals, particularly for underserved conditions such as uterine fibroids and female sexual dysfunction. Mergers and acquisitions are also being used to consolidate market presence and gain access to innovative technologies.